Clinical trial results:
A Phase 1b/2 study to assess the safety, tolerability and efficacy of BGB-290 in combination with radiation therapy and/or temozolomide in subjects with first-line or recurrent/refractory glioblastoma

Summary

EudraCT number	2017-001554-33
Trial protocol	NL
Global end of trial date	17 March 2021

Results information

Result version number	v2 (current)
This version publication date	22 June 2022
First version publication date	19 March 2022
Version creation reason	• Correction of full data set Time frame needed to be changed

Trial information

Trial identification

Sponsor protocol code	BGB-290-104

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03150862
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	BeiGene, Ltd
Sponsor organisation address	2955 Campus Drive, Suite 200, San Mateo, CA , United States, 94403
Public contact	Clinical Trial Information Email, BeiGene USA, Inc., +1 877-828-5568 , clinicaltrials@beigene.com
Scientific contact	Clinical Trial Information Email, BeiGene USA, Inc., +1 877-828-5568 , clinicaltrials@beigene.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	13 April 2021
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	17 March 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

PHASE 1:
1) Arm A:
• To assess safety and tolerability of BGB-290 combined with RT
• To identify dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) for BGB-290 combined with RT
• To select the recommended Phase 2 schedule for full-dose BGB 290 combined with RT

2) Arm B:
• To assess safety and tolerability of BGB-290 combined with RT and TMZ
• To identify DLTs and determine the MTD or MAD for TMZ combined with RT and the MTD/MAD for BGB-290 of Arm A
• To select the RP2D for TMZ combined with RT and the MTD/MAD for BGB-290 of Arm A

3) Arm C:
• To assess safety and tolerability of BGB-290 combined with TMZ
• To identify DLTs and determine the MTD or MAD for TMZ combined with full-dose BGB-290
• To select the RP2D for TMZ combined with full-dose BGB 290

PHASE 2:

To assess the efficacy of BGB-290 combined with:
1) RT (Arm A)
2) RT and TMZ (Arm B)
3) TMZ (Arm C)

Protection of trial subjects:

This study was conducted in accordance with Sponsor procedures, which comply with the principles of Good Clinical Practice, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guidelines, the Declaration of Helsinki, and local regulatory requirements.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	24 July 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 4
Country: Number of subjects enrolled	Switzerland: 1
Country: Number of subjects enrolled	United States: 111

Worldwide total number of subjects	116
EEA total number of subjects	4

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	84
From 65 to 84 years	31
85 years and over	1

Subject disposition

Recruitment

Recruitment details:

This study was conducted in 20 centers and 116 participants were treated.

Pre-assignment

Screening details:

This study consisted of a dose escalation phase and a dose expansion phase. A total of 116 participants were recruited in Netherlands, Switzerland and United States.

Period 1

Period 1 title	Overall period (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Arm A: Dose Escalation (DE) - Pamiparib 2Wks + RT 6 Wks

Arm description:

Participants with newly diagnosed unmethylated glioblastoma (GBM) received 60 milligrams (mg) pamiparib orally twice daily (BID) for 2 weeks in combination with up to 60 Gy radiation for 6 weeks

Arm type	Experimental
Investigational medicinal product name	Pamiparib
Investigational medicinal product code	BGB-290
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

60 mg pamiparib BID for 2 weeks in combination with up to 60 Gy radiation for 6 weeks

Arm title	Arm A: DE-Pamiparib 4 Wks + RT 6 Wks

Arm description:

Participants with newly diagnosed unmethylated GBM received 60 mg pamiparib orally for 4 weeks in combination with up to 60 Gy radiation for 6 weeks

Arm type	Experimental
Investigational medicinal product name	Pamiparib
Investigational medicinal product code	BGB-290
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

60 mg pamiparib BID for 4 weeks in combination with up to 60 Gy radiation for 6 weeks

Arm title	Arm A: DE- Pamiparib 6Wks + RT 6 Wks

Arm description:

Participants with newly diagnosed unmethylated GBM received 60 mg pamiparib orally for 6 weeks in combination with up to 60 Gy radiation for 6 weeks

Arm type	Experimental

Investigational medicinal product name	Pamiparib
Investigational medicinal product code	BGB-290
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

60 mg pamiparib BID for 6 weeks in combination with up to 60 Gy radiation for 6 weeks

Arm title	Arm A: Dose Expansion (E) - Pamiparib 6 Wks + RT 6 Wks

Arm description:

Participants with newly diagnosed unmethylated GBM received 60 mg pamiparib orally for 6 weeks in combination with up to 60 Gy radiation for 6 weeks

Arm type	Experimental
Investigational medicinal product name	Pamiparib
Investigational medicinal product code	BGB-290
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

60 mg pamiparib BID for 6 weeks in combination with up to 60 Gy radiation for 6 weeks

Arm title	Arm B: DE-Pamiparib 6 Wks + RT 6 Wks + + Temozolomide

Arm description:

Participants with newly diagnosed unmethylated GBM received 60 mg pamiparib orally for 6 weeks in combination with up to 60 Gy radiation for 6 weeks and 60 mg temozolomide Wks 1 and 5

Arm type	Experimental
Investigational medicinal product name	Pamiparib
Investigational medicinal product code	BGB-290
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

60 mg pamiparib BID for 6 weeks in combination with up to 60 Gy radiation for 6 weeks

Investigational medicinal product name	Temozolomide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

60 mg temozolomide wks 1 and 5

Arm title	Arm C: DE – Pamiparib + Temozolomide 20 mg

Arm description:

Participants with both methylated and unmethylated recurrent/refractory GBM received 60 mg pamiparib BID and 20 mg temozolomide once daily orally from Day 1 to Day 21

Arm type	Experimental
Investigational medicinal product name	Pamiparib
Investigational medicinal product code	BGB-290
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

60 mg pamiparib BID for 6weeks in combination with up to 60 Gy radiation for 6 weeks

Investigational medicinal product name	Temozolomide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

temozolomide 40 mg once daily from Day 1 to day 21

Arm title	Arm C: DE – Pamiparib + Temozolomide 40 mg

Arm description:

Participants with both methylated and unmethylated recurrent/refractory GBM received 60 mg pamiparib BID and 40 mg temozolomide once daily orally from Day 1 to Day 21

Arm type	Experimental
Investigational medicinal product name	Temozolomide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

temozolomide 40 mg once daily from Day 1 to day 21

Arm title	Arm C: E- Pamiparib + Temozolomide 60 mg

Arm description:

Participants with both methylated and unmethylated recurrent/refractory GBM received 60 mg pamiparib BID and 60 mg temozolomide once daily orally from Day 1 to Day 7

Arm type	Experimental
Investigational medicinal product name	Temozolomide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

temozolomide 60 mg once daily from Day 1 to day 21

Number of subjects in period 1	Arm A: Dose Escalation (DE) - Pamiparib 2Wks + RT 6 Wks	Arm A: DE-Pamiparib 4 Wks + RT 6 Wks	Arm A: DE-Pamiparib 6Wks + RT 6 Wks
Started	3	8	9
Completed	0	0	0
Not completed	3	8	9
Consent withdrawn by subject	1	1	-
Sponsor's Decision	-	-	-
Roll-Over to Long term	-	-	-
Death	2	7	8
Progressive Disease	-	-	-
Lost to follow-up	-	-	1
Change in Methylation status	-	-	-

Number of subjects in period 1	Arm A: Dose Expansion (E) - Pamiparib 6 Wks + RT 6 Wks	Arm B: DE- Pamiparib 6 Wks + RT 6 Wks + + Temozolomide	Arm C: DE – Pamiparib + Temozolomide 20 mg
Started	40	9	9
Completed	0	0	0
Not completed	40	9	9
Consent withdrawn by subject	3	1	1
Sponsor's Decision	10	3	-
Roll-Over to Long term	-	-	-
Death	27	4	8
Progressive Disease	-	-	-
Lost to follow-up	-	-	-
Change in Methylation status	-	1	-

Number of subjects in period 1	Arm C: DE – Pamiparib + Temozolomide 40 mg	Arm C: E- Pamiparib + Temozolomide 60 mg
Started	8	30
Completed	0	0
Not completed	8	30
Consent withdrawn by subject	1	3
Sponsor's Decision	1	1
Roll-Over to Long term	-	1
Death	6	21
Progressive Disease	-	2
Lost to follow-up	-	2
Change in Methylation status	-	-

Baseline characteristics

Reporting groups	
Reporting group title	Arm A: Dose Escalation (DE) - Pamiparib 2Wks + RT 6 Wks
Reporting group description:	
Participants with newly diagnosed unmethylated glioblastoma (GBM) received 60 milligrams (mg) pamiparib orally twice daily (BID) for 2 weeks in combination with up to 60 Gy radiation for 6 weeks	
Reporting group title	Arm A: DE-Pamiparib 4 Wks + RT 6 Wks
Reporting group description:	
Participants with newly diagnosed unmethylated GBM received 60 mg pamiparib orally for 4 weeks in combination with up to 60 Gy radiation for 6 weeks	
Reporting group title	Arm A: DE- Pamiparib 6Wks + RT 6 Wks
Reporting group description:	
Participants with newly diagnosed unmethylated GBM received 60 mg pamiparib orally for 6 weeks in combination with up to 60 Gy radiation for 6 weeks	
Reporting group title	Arm A: Dose Expansion (E) - Pamiparib 6 Wks + RT 6 Wks
Reporting group description:	
Participants with newly diagnosed unmethylated GBM received 60 mg pamiparib orally for 6 weeks in combination with up to 60 Gy radiation for 6 weeks	
Reporting group title	Arm B: DE-Pamiparib 6 Wks + RT 6 Wks + + Temozolomide
Reporting group description:	
Participants with newly diagnosed unmethylated GBM received 60 mg pamiparib orally for 6 weeks in combination with up to 60 Gy radiation for 6 weeks and 60 mg temozolomide Wks 1 and 5	
Reporting group title	Arm C: DE – Pamiparib + Temozolomide 20 mg
Reporting group description:	
Participants with both methylated and unmethylated recurrent/refractory GBM received 60 mg pamiparib BID and 20 mg temozolomide once daily orally from Day 1 to Day 21	
Reporting group title	Arm C: DE – Pamiparib + Temozolomide 40 mg
Reporting group description:	
Participants with both methylated and unmethylated recurrent/refractory GBM received 60 mg pamiparib BID and 40 mg temozolomide once daily orally from Day 1 to Day 21	
Reporting group title	Arm C: E- Pamiparib + Temozolomide 60 mg
Reporting group description:	
Participants with both methylated and unmethylated recurrent/refractory GBM received 60 mg pamiparib BID and 60 mg temozolomide once daily orally from Day 1 to Day 7	

Reporting group values	Arm A: Dose Escalation (DE) - Pamiparib 2Wks + RT 6 Wks	Arm A: DE-Pamiparib 4 Wks + RT 6 Wks	Arm A: DE-Pamiparib 6Wks + RT 6 Wks
Number of subjects	3	8	9
Age categorical			
Units: Subjects			
Age continuous			
Units: years			
arithmetic mean	59.7	63.4	58.8
standard deviation	± 8.39	± 8.80	± 7.66
Gender categorical			
Units: Subjects			
Female	0	1	2
Male	3	7	7

Race/Ethnicity, Customized Units: Subjects			
Asian	0	0	1
Black or African American	0	1	1
White	3	7	7
Unknown/Not Reported	0	0	0

Reporting group values	Arm A: Dose Expansion (E) - Pamiparib 6 Wks + RT 6 Wks	Arm B: DE- Pamiparib 6 Wks + RT 6 Wks + + Temozolomide	Arm C: DE – Pamiparib + Temozolomide 20 mg
Number of subjects	40	9	9
Age categorical Units: Subjects			
Age continuous Units: years			
arithmetic mean	56.7	60.9	49.2
standard deviation	± 13.48	± 9.94	± 12.63
Gender categorical Units: Subjects			
Female	17	4	1
Male	23	5	8
Race/Ethnicity, Customized Units: Subjects			
Asian	0	0	0
Black or African American	0	0	1
White	38	9	7
Unknown/Not Reported	2	0	1

Reporting group values	Arm C: DE – Pamiparib + Temozolomide 40 mg	Arm C: E- Pamiparib + Temozolomide 60 mg	Total
Number of subjects	8	30	116
Age categorical Units: Subjects			
Age continuous Units: years			
arithmetic mean	49.1	58.6	
standard deviation	± 15.51	± 10.54	-
Gender categorical Units: Subjects			
Female	4	10	39
Male	4	20	77
Race/Ethnicity, Customized Units: Subjects			
Asian	0	1	2
Black or African American	0	0	3
White	8	27	106
Unknown/Not Reported	0	2	5

End points

End points reporting groups

Reporting group title	Arm A: Dose Escalation (DE) - Pamiparib 2Wks + RT 6 Wks
Reporting group description:	
Participants with newly diagnosed unmethylated glioblastoma (GBM) received 60 milligrams (mg) pamiparib orally twice daily (BID) for 2 weeks in combination with up to 60 Gy radiation for 6 weeks	
Reporting group title	Arm A: DE-Pamiparib 4 Wks + RT 6 Wks
Reporting group description:	
Participants with newly diagnosed unmethylated GBM received 60 mg pamiparib orally for 4 weeks in combination with up to 60 Gy radiation for 6 weeks	
Reporting group title	Arm A: DE- Pamiparib 6Wks + RT 6 Wks
Reporting group description:	
Participants with newly diagnosed unmethylated GBM received 60 mg pamiparib orally for 6 weeks in combination with up to 60 Gy radiation for 6 weeks	
Reporting group title	Arm A: Dose Expansion (E) - Pamiparib 6 Wks + RT 6 Wks
Reporting group description:	
Participants with newly diagnosed unmethylated GBM received 60 mg pamiparib orally for 6 weeks in combination with up to 60 Gy radiation for 6 weeks	
Reporting group title	Arm B: DE-Pamiparib 6 Wks + RT 6 Wks + + Temozolomide
Reporting group description:	
Participants with newly diagnosed unmethylated GBM received 60 mg pamiparib orally for 6 weeks in combination with up to 60 Gy radiation for 6 weeks and 60 mg temozolomide Wks 1 and 5	
Reporting group title	Arm C: DE – Pamiparib + Temozolomide 20 mg
Reporting group description:	
Participants with both methylated and unmethylated recurrent/refractory GBM received 60 mg pamiparib BID and 20 mg temozolomide once daily orally from Day 1 to Day 21	
Reporting group title	Arm C: DE – Pamiparib + Temozolomide 40 mg
Reporting group description:	
Participants with both methylated and unmethylated recurrent/refractory GBM received 60 mg pamiparib BID and 40 mg temozolomide once daily orally from Day 1 to Day 21	
Reporting group title	Arm C: E- Pamiparib + Temozolomide 60 mg
Reporting group description:	
Participants with both methylated and unmethylated recurrent/refractory GBM received 60 mg pamiparib BID and 60 mg temozolomide once daily orally from Day 1 to Day 7	

Primary: Phase 1b Escalation Phase: Number of Participants with Dose-Limiting Toxicities (DLTs) as assessed by CTCAE

End point title	Phase 1b Escalation Phase: Number of Participants with Dose-Limiting Toxicities (DLTs) as assessed by CTCAE[1][2]
End point description:	
A DLT is defined as one of the following toxicities occurring during the DLT assessment window: Grade ≥3 non-hematologic, non-hepatic major organ adverse event (AE) Grade 4 neutropenia lasting >7 days Grade ≥3 febrile neutropenia Grade 3 thrombocytopenia with clinically significant bleeding Grade 4 thrombocytopenia lasting > 3 days and requiring transfusion, or any decreased platelet count <15,000/mm3/ <15.0 x 109/L Grade ≥4 anemia Grade ≥3 total bilirubin or hepatic transaminases (ALT [SGPT] or AST [SGOT])	
End point type	Primary
End point timeframe:	
Arm A:Day 1 Pamiparib dose until 4 weeks after the last RT; Arm B: Day 1 of Pamiparib and Temozolomide until 4	

weeks after the last RT; Arm C: 1st cycle of 28 days

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Endpoint is descriptive and no statistical analyses were performed per protocol

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: DLTs were collected only for escalation phase per protocol

End point values	Arm A: Dose Escalation (DE) - Pamiparib 2Wks + RT 6 Wks	Arm A: DE-Pamiparib 4 Wks + RT 6 Wks	Arm A: DE-Pamiparib 6Wks + RT 6 Wks	Arm B: DE-Pamiparib 6 Wks + RT 6 Wks + + Temozolomide
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	8	9	9
Units: Number of participants	0	0	2	1

End point values	Arm C: DE – Pamiparib + Temozolomide 20 mg	Arm C: DE – Pamiparib + Temozolomide 40 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	8		
Units: Number of participants	0	3		

Statistical analyses

No statistical analyses for this end point

Primary: Phase 1b Escalation Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) as Assessed by CTCAE

End point title	Phase 1b Escalation Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) as Assessed by CTCAE[3][4]

End point description:

Safety analysis Set;
A treatment-emergent adverse event (TEAE) is defined as an AE that had an onset date on or after first dose of study treatment or was worsening in severity from baseline (pretreatment) up to 30 days following permanent study treatment discontinuation or initiation of new anti-cancer therapy, whichever occurs first.
An SAE is any untoward medical occurrence that, at any dose meets at least one of the following criteria: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is considered a significant medical AE based on medical judgment. SAEs were collected from the day the participant signs the Informed Consent Form (ICF). SAEs were collected from the day the participant signs the Informed Consent Form (ICF).

End point type	Primary

End point timeframe:

From initiation of study treatment (for TEAE) or from the date informed consent has been signed (for SAE), until 30
days after last study treatment or initiation of new anticancer therapy, whichever occurs first

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Endpoint is descriptive and no statistical analyses were performed per protocol

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Phase 1b data are reported per protocol

End point values	Arm A: Dose Escalation (DE) - Pamiparib 2Wks + RT 6 Wks	Arm A: DE-Pamiparib 4 Wks + RT 6 Wks	Arm A: DE-Pamiparib 6Wks + RT 6 Wks	Arm B: DE-Pamiparib 6 Wks + RT 6 Wks + + Temozolomide
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	8	9	9
Units: Number of participants				
Participants with At Least 1 TEAE	3	8	9	9
TEAE with Grade 3 or Higher	1	3	4	4
Treatment Emergent SAEs	0	2	2	2
TEAE Leading to Death	0	0	0	0

End point values	Arm C: DE – Pamiparib + Temozolomide 20 mg	Arm C: DE – Pamiparib + Temozolomide 40 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	8		
Units: Number of participants				
Participants with At Least 1 TEAE	9	8		
TEAE with Grade 3 or Higher	5	7		
Treatment Emergent SAEs	4	3		
TEAE Leading to Death	0	0		

Statistical analyses

No statistical analyses for this end point

Primary: Phase 1b Escalation Phase Arm C: Number of Participants with Clinically Relevant Changes in Vital signs and Clinical Laboratory Measurements

End point title	Phase 1b Escalation Phase Arm C: Number of Participants with Clinically Relevant Changes in Vital signs and Clinical Laboratory Measurements[5][6]

End point description:

End point type	Primary

End point timeframe:

From the date of first dose up to end of study (EOS) visit (up to 3 years and 7.5 months)

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Endpoint is descriptive and no statistical analyses were performed per protocol

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Arms C data are reported per protocol.

End point values	Arm C: DE – Pamiparib + Temozolomide 20 mg	Arm C: DE – Pamiparib + Temozolomide 40 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	8		
Units: Number of Participants	0	0		

Statistical analyses

No statistical analyses for this end point

Primary: Phase 2 Arm A Expansion Phase: Modified Disease Control Rate as Assessed by Response Assessment in Neuro-Oncology (RANO) Criteria

End point title	Phase 2 Arm A Expansion Phase: Modified Disease Control Rate as Assessed by Response Assessment in Neuro-Oncology (RANO) Criteria[7][8]

End point description:

Modified DCR is defined as the percentage of participants with complete response (CR), partial response (PR) or stable disease (SD) per RANO criteria as the response assessment at the end-of-treatment (EOT) visit. The Efficacy Analysis Set includes participants in the Safety Analysis Set who had a tumor assessment at baseline and at End of Treatment unless discontinued treatment or study early due to disease progression or death prior to tumor assessment.

End point type	Primary

End point timeframe:

From the date of first dose up to EOS visit (3 years and 7.5 months)

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Endpoint is descriptive and no statistical analyses were performed per protocol

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Arm A data are reported per protocol.

End point values	Arm A: Dose Expansion (E) - Pamiparib 6 Wks + RT 6 Wks			
Subject group type	Reporting group			
Number of subjects analysed	32			
Units: Percentage of participants				
number (confidence interval 95%)	65.6 (46.8 to 81.4)			

Statistical analyses

No statistical analyses for this end point

Primary: Phase 2 Arm C: Objective Response Rate (ORR) as Assessed Using RANO Criteria

End point title	Phase 2 Arm C: Objective Response Rate (ORR) as Assessed Using RANO Criteria[9][10]

End point description:

ORR (objective response rate) is defined as percentage of participants with best overall response of CR or PR per RANO criteria (confirmed by a subsequent tumor assessment at least four weeks apart). The Efficacy Analysis Set includes participants in the Safety Analysis Set who had measurable disease at baseline and at least one postbaseline tumor assessment unless discontinued treatment or study early due to disease progression or death prior to tumor assessment.

End point type	Primary

End point timeframe:

From the date of first dose up to first documentation of disease progression while participant is alive (3 years and 7.5 months)

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Endpoint is descriptive and no statistical analyses were performed per protocol

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Arms C data are reported per protocol.

End point values	Arm C: E-Pamiparib + Temozolomide 60 mg			
Subject group type	Reporting group			
Number of subjects analysed	28			
Units: Percentage of participants				
number (confidence interval 95%)	3 (2.3 to 28.2)			

Statistical analyses

No statistical analyses for this end point

Primary: Phase 1b Arm C: Number of Cycles of Treatment Received by Participants

End point title	Phase 1b Arm C: Number of Cycles of Treatment Received by Participants[11][12]

End point description:

Data shows the percentage of participants who received treatment for the given number of cycles.

End point type	Primary

End point timeframe:

From the date of first dose up to EOS visit (up to 3 years and 7.5 months)

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Endpoint is descriptive and no statistical analyses were performed per protocol

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Arm C data are reported per protocol.

End point values	Arm C: DE – Pamiparib + Temozolomide 20 mg	Arm C: DE – Pamiparib + Temozolomide 40 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	8		
Units: Percentage of participants				
number (not applicable)				
<1 cycle	22.2	37.5		
1 cycle	44.4	0		
2 cycles	11.1	25.0		
3 cycles	0	12.5		
4 cycles	11.1	0		
5 cycles	11.1	0		
6 cycles	0	0		
7 cycles	0	0		
>7 cycles	0	25.0		

Statistical analyses

No statistical analyses for this end point

Primary: Phase 1b Arm C: Average Dose Intensity of Pamiparib And TMZ Received per Participant

End point title	Phase 1b Arm C: Average Dose Intensity of Pamiparib And TMZ Received per Participant[13][14]

End point description:

End point type	Primary

End point timeframe:

From the date of first dose until EOS visit (up to 3 years and 7.5 months)

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Endpoint is descriptive and no statistical analyses were performed per protocol

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Arm C data are reported per protocol.

End point values	Arm C: DE – Pamiparib + Temozolomide 20 mg	Arm C: DE – Pamiparib + Temozolomide 40 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	8		
Units: Milligrams/Day				
arithmetic mean (standard deviation)				
Pamiparib	97.5 (± 25.41)	107.6 (± 14.65)		
TMZ	13.6 (± 1.88)	28.2 (± 10.80)		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1B and Phase 2:Pharmacokinetics: Ctrough of Pamiparib

End point title	Phase 1B and Phase 2:Pharmacokinetics: Ctrough of Pamiparib

End point description:

The Pharmacokinetic Analysis Set includes all participants for whom valid pamiparib PK parameters can be estimated. Participants with available data were included in the analysis.

End point type	Secondary

End point timeframe:

Pre-dose, 2 hours post dose on Days 1 and 15 of radiation Therapy

End point values	Arm A: Dose Escalation (DE) - Pamiparib 2Wks + RT 6 Wks	Arm A: DE-Pamiparib 4 Wks + RT 6 Wks	Arm A: DE-Pamiparib 6Wks + RT 6 Wks	Arm A: Dose Expansion (E) - Pamiparib 6 Wks + RT 6 Wks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	5	6	35
Units: ng/mL				
arithmetic mean (standard deviation)	891.3 (± 444.51)	1817.0 (± 1226.53)	1848.3 (± 784.38)	2239.9 (± 1011.07)

End point values	Arm B: DE-Pamiparib 6 Wks + RT 6 Wks + + Temozolomide	Arm C: DE – Pamiparib + Temozolomide 20 mg	Arm C: DE – Pamiparib + Temozolomide 40 mg	Arm C: E-Pamiparib + Temozolomide 60 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	6	6	25
Units: ng/mL				
arithmetic mean (standard deviation)	2134.3 (± 953.06)	1893.3 (± 718.46)	1550.8 (± 1422.55)	1500.2 (± 943.35)

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1b Arm A and Arm B Escalation Phase: Modified Disease Control Rate as Assessed by RANO Criteria

End point title	Phase 1b Arm A and Arm B Escalation Phase: Modified Disease Control Rate as Assessed by RANO Criteria[15]

End point description:

Modified DCR is defined as the percentage of participants with complete response (CR), partial response (PR) or stable disease (SD) per RANO criteria as the response assessment at the end-of-treatment (EOT) visit. Efficacy Analysis Set

End point type	Secondary

End point timeframe:

From the date of first dose up to first documentation of disease progression while participant is alive (3 years and 7.5 months)

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Arms a and B data are reported per protocol.

End point values	Arm A: Dose Escalation (DE) - Pamiparib 2Wks + RT 6 Wks	Arm A: DE-Pamiparib 4 Wks + RT 6 Wks	Arm A: DE-Pamiparib 6Wks + RT 6 Wks	Arm B: DE-Pamiparib 6 Wks + RT 6 Wks + + Temozolomide
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	6	7	5
Units: Percentage of participants				
number (confidence interval 95%)	66.7 (9.4 to 99.2)	100.0 (54.1 to 100.0)	42.9 (9.9 to 81.6)	80.0 (28.4 to 99.5)

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1b Escalation Phase Arm C: Disease Control Rate as Assessed by RANO Criteria

End point title	Phase 1b Escalation Phase Arm C: Disease Control Rate as Assessed by RANO Criteria[16]

End point description:

DCR is defined as the percentage of participants with best overall response of CR, PR or SD per RANO criteria. CR or PR will be confirmed by a subsequent tumor assessment at least four weeks apart. Efficacy Analysis Set

End point type	Secondary

End point timeframe:

From the date of first dose up to first documentation of disease progression while participant is alive (3 years and 7.5 months)

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Arm C data are reported per protocol.

End point values	Arm C: DE – Pamiparib + Temozolomide 20 mg	Arm C: DE – Pamiparib + Temozolomide 40 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	7		
Units: Percentage of participants				
number (confidence interval 95%)	55.6 (21.2 to 86.3)	71.4 (29.0 to 96.3)		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1b and Phase 2 Arms A and B: ORR as Assessed Using RANO Criteria

End point title	Phase 1b and Phase 2 Arms A and B: ORR as Assessed Using RANO Criteria[17]

End point description:

ORR is defined as percentage of participants with best overall response of CR or PR per RANO criteria (confirmed by a subsequent tumor assessment at least four weeks apart). Efficacy Analysis Set

End point type	Secondary

End point timeframe:

From the date of first dose up to first documentation of disease progression while participant is alive (3 years and 7.5 months)

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Arms a and B data are reported per protocol.

End point values	Arm A: Dose Escalation (DE) - Pamiparib 2Wks + RT 6 Wks	Arm A: DE-Pamiparib 4 Wks + RT 6 Wks	Arm A: DE-Pamiparib 6Wks + RT 6 Wks	Arm A: Dose Expansion (E) - Pamiparib 6 Wks + RT 6 Wks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	6	7	32
Units: Percentage of participants				
number (confidence interval 95%)	0 (0.0 to 70.8)	16.7 (0.4 to 64.1)	0 (0.0 to 41.0)	3.1 (0.1 to 16.2)

End point values	Arm B: DE-			

	Pamiparib 6 Wks + RT 6 Wks + + Temozolomide			
Subject group type	Reporting group			
Number of subjects analysed	5			
Units: Percentage of participants				
number (confidence interval 95%)	0 (0.0 to 52.2)			

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1b and Phase2 Arms A, B and C: Clinical Benefit Rate as Assessed Using RANO Criteria

End point title	Phase 1b and Phase2 Arms A, B and C: Clinical Benefit Rate as Assessed Using RANO Criteria

End point description:

Clinical benefit rate (CBR) is defined as the percentage of participants with best overall response of CR, PR or SD ≥ 24 weeks per RANO criteria (confirmed by a subsequent tumor assessment at least four weeks apart). Efficacy Analysis Set

End point type	Secondary

End point timeframe:

From the date of first dose up to first documentation of disease progression while participant is alive (3 years and 7.5 months)

End point values	Arm A: Dose Escalation (DE) - Pamiparib 2Wks + RT 6 Wks	Arm A: DE-Pamiparib 4 Wks + RT 6 Wks	Arm A: DE-Pamiparib 6Wks + RT 6 Wks	Arm A: Dose Expansion (E) - Pamiparib 6 Wks + RT 6 Wks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	6	7	32
Units: Percentage of participants				
number (confidence interval 95%)	0 (0.0 to 70.8)	33.3 (4.3 to 77.7)	0 (0.0 to 41.0)	37.6 (21.1 to 56.34)

End point values	Arm B: DE-Pamiparib 6 Wks + RT 6 Wks + + Temozolomide	Arm C: DE – Pamiparib + Temozolomide 20 mg	Arm C: DE – Pamiparib + Temozolomide 40 mg	Arm C: E-Pamiparib + Temozolomide 60 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	9	7	28
Units: Percentage of participants				
number (confidence interval 95%)	40.0 (5.3 to 85.3)	0 (0.0 to 33.6)	28.6 (3.7 to 71.0)	17.9 (6.1 to 36.9)

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1b and Phase 2 Arms A, B and C: Duration of Response (DOR) as Assessed Using RANO Criteria

End point title	Phase 1b and Phase 2 Arms A, B and C: Duration of Response (DOR) as Assessed Using RANO Criteria

End point description:

DOR is defined as the time from the date of the earliest documented response to disease progression or death for any cause whichever occurs earlier. Efficacy Analysis Set; 9999 = Not estimable due to insufficient number of events

End point type	Secondary

End point timeframe:

From first documentation of CR or PR to first documentation of disease progression or death (up to 3 years and 7.5 months)

End point values	Arm A: Dose Escalation (DE) - Pamiparib 2Wks + RT 6 Wks	Arm A: DE-Pamiparib 4 Wks + RT 6 Wks	Arm A: DE-Pamiparib 6Wks + RT 6 Wks	Arm A: Dose Expansion (E) - Pamiparib 6 Wks + RT 6 Wks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0[18]	1	0[19]	1[20]
Units: Months				
median (confidence interval 95%)	(to)	6.44 (-9999 to 9999)	(to)	10.32 (-9999 to 9999)

Notes:

[18] - Only the participants with objective responses were included in DOR analysis.

[19] - Only the participants with objective responses were included in DOR analysis.

[20] - Only the participants with objective responses were included in DOR analysis.

End point values	Arm B: DE-Pamiparib 6 Wks + RT 6 Wks + + Temozolomide	Arm C: DE – Pamiparib + Temozolomide 20 mg	Arm C: DE – Pamiparib + Temozolomide 40 mg	Arm C: E-Pamiparib + Temozolomide 60 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0[21]	0[22]	1	3
Units: Months				
median (confidence interval 95%)	(to)	(to)	11.7 (-9999 to 9999)	9999 (12.68 to 9999)

Notes:

[21] - Only the participants with objective responses were included in DOR analysis.

[22] - Only the participants with objective responses were included in DOR analysis.

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1b and Phase2 Arms A, B and C: Progression free survival (PFS) as Assessed Using RANO Criteria

End point title	Phase 1b and Phase2 Arms A, B and C: Progression free survival (PFS) as Assessed Using RANO Criteria

End point description:

PFS is defined as the time from the first dose date to disease progression per RANO criteria or death, whichever occurs first.
9999 = Not estimable to due to insufficient number of events

End point type	Secondary

End point timeframe:

From the date of first dose up to first documentation of disease progression or death (up to 3 years and 7.5 months)

End point values	Arm A: Dose Escalation (DE) - Pamiparib 2Wks + RT 6 Wks	Arm A: DE-Pamiparib 4 Wks + RT 6 Wks	Arm A: DE-Pamiparib 6Wks + RT 6 Wks	Arm A: Dose Expansion (E) - Pamiparib 6 Wks + RT 6 Wks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	8	9	40
Units: Months				
median (confidence interval 95%)	3.12 (2.79 to 3.29)	8.94 (3.78 to 11.56)	2.56 (2.14 to 9999)	4.44 (3.29 to 6.24)

End point values	Arm B: DE-Pamiparib 6 Wks + RT 6 Wks + + Temozolomide	Arm C: DE – Pamiparib + Temozolomide 20 mg	Arm C: DE – Pamiparib + Temozolomide 40 mg	Arm C: E-Pamiparib + Temozolomide 60 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	9	8	30
Units: Months				
median (confidence interval 95%)	5.75 (2.37 to 6.47)	1.81 (0.82 to 3.48)	2.66 (0.66 to 7.39)	1.87 (1.48 to 1.91)

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1b and Phase2 Arms A, B and C: Overall survival (OS)

End point title	Phase 1b and Phase2 Arms A, B and C: Overall survival (OS)

End point description:

OS is defined as the time from the first dose date to date of death for any cause. 9999 = Not estimable due to insufficient number of events.

End point type	Secondary

End point timeframe:

From the date of first dose up to EOS visit (3 years and 7.5 months)

End point values	Arm A: Dose Escalation (DE) - Pamiparib 2Wks + RT 6 Wks	Arm A: DE-Pamiparib 4 Wks + RT 6 Wks	Arm A: DE-Pamiparib 6Wks + RT 6 Wks	Arm A: Dose Expansion (E) - Pamiparib 6 Wks + RT 6 Wks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	8	9	40
Units: Months				
median (confidence interval 95%)	14.46 (13.93 to 14.98)	13.44 (4.14 to 20.24)	10.25 (4.44 to 19.84)	12.71 (9.79 to 14.46)

End point values	Arm B: DE-Pamiparib 6 Wks + RT 6 Wks + + Temozolomide	Arm C: DE – Pamiparib + Temozolomide 20 mg	Arm C: DE – Pamiparib + Temozolomide 40 mg	Arm C: E-Pamiparib + Temozolomide 60 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	9	8	30
Units: Months				
median (confidence interval 95%)	14.23 (7.98 to 9999)	6.00 (2.60 to 9.79)	8.62 (2.96 to 9999)	7.79 (6.21 to 10.68)

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2 Arms A and C Expansion Phase: Number of Participants with Treatment Emergent adverse events (TEAEs) and Serious adverse events (SAEs)

End point title	Phase 2 Arms A and C Expansion Phase: Number of Participants with Treatment Emergent adverse events (TEAEs) and Serious adverse events (SAEs)[23]

End point description:

A treatment-emergent adverse event (TEAE) is defined as an AE that had an onset date on or after first dose of study treatment or was worsening in severity from baseline (pretreatment) up to 30 days following permanent study treatment discontinuation or initiation of new anti-cancer therapy, whichever occurs first.
An SAE is any untoward medical occurrence that, at any dose meets at least one of the following criteria: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is considered a significant medical AE based on medical judgment. SAEs were collected from the day the participant signs the Informed Consent Form (ICF).

End point type	Secondary

End point timeframe:

From initiation of study treatment (for TEAE) or from the date informed consent has been signed (for SAE), until 30
days after last study treatment or initiation of new anticancer therapy, whichever occurs first

Notes:

[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Arms A and C data are reported per protocol.

End point values	Arm A: Dose Expansion (E) - Pamiparib 6 Wks + RT 6 Wks	Arm C: E-Pamiparib + Temozolomide 60 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	40	30		
Units: Number of participants				
Participants with at Lease 1 TEAE	40	29		
TEAE with Grade 3 or Higher	25	19		
Treatment Emergent SAEs	18	11		
TEAE Leading to Death	3	1		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2 Expansion Phase Arm A and C: Number of Participants with Clinically Relevant Changes in Vital signs and Clinical Laboratory Measurements

End point title	Phase 2 Expansion Phase Arm A and C: Number of Participants with Clinically Relevant Changes in Vital signs and Clinical Laboratory Measurements[24]

End point description:

End point type	Secondary

End point timeframe:

From the date of first dose up to EOS visit (3 years and 7.5 months)

Notes:

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Arms A and C data are reported per protocol

End point values	Arm A: Dose Expansion (E) - Pamiparib 6 Wks + RT 6 Wks	Arm C: E-Pamiparib + Temozolomide 60 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	40	30		
Units: Number of participants	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2 Arms A and C Expansion Phase: Number of Cycles of Treatment Received by Participants

End point title	Phase 2 Arms A and C Expansion Phase: Number of Cycles of Treatment Received by Participants[25]

End point description:

Data shows the percentage of participants who received treatment for the given number of cycles.

End point type	Secondary

End point timeframe:

From date of first dose up to EOS Visit (up to 3 years and 7.5 months)

Notes:

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Arms A and C data are reported per protocol

End point values	Arm A: Dose Expansion (E) - Pamiparib 6 Wks + RT 6 Wks	Arm C: E-Pamiparib + Temozolomide 60 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	40	30		
Units: Percentage of participants				
number (not applicable)				
<1 cycle	10.3	26.7		
1 cycle	31.0	26.7		
3 cycles	6.9	3.3		
2 cycles	6.9	23.3		
4 cycles	10.3	3.3		
5 cycles	10.3	0.0		
6 cycles	10.3	0.0		
7 cycles	0.0	0.0		
>7 cycles	13.8	16.7		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2 Arms A and C Expansion Phase: Average Dose Intensity of Pamiparib and TMZ Received per Participant

End point title	Phase 2 Arms A and C Expansion Phase: Average Dose Intensity of Pamiparib and TMZ Received per Participant[26]

End point description:

9999 = Not applicable since no TMZ was administered in this arm

End point type	Secondary

End point timeframe:

From date of first dose up to EOS Visit (up to 3 years and 7.5 months)

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Arms A and C data are reported per protocol.

End point values	Arm A: Dose Expansion (E) - Pamiparib 6 Wks + RT 6 Wks	Arm C: E-Pamiparib + Temozolomide 60 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	40	30		
Units: Milligrams/Day				
arithmetic mean (standard deviation)				
Pamiparib	109.0 (± 22.07)	109.5 (± 15.22)		
TMZ	9999 (± 9999)	19.6 (± 11.60)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From initiation of study treatment (for TEAE) or from the date informed consent has been signed (for SAE), until
30 days after last study treatment or initiation of new anticancer therapy, whichever occurs first

Adverse event reporting additional description:

A treatment-emergent adverse event (TEAE) is defined as an AE that had an onset date on or after first dose of study treatment or was worsening in severity from baseline (pretreatment) up to 30 days following permanent study treatment discontinuation or initiation of new anti-cancer therapy, whichever occurs first.
An SAE is any untoward medical o

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	23.0

Reporting groups

Reporting group title	Arm 1Arm A: DE - Pamiparib 2 Wks + Radiation Therapy (RT) 6 Wk

Reporting group description:

Participants with newly diagnosed unmethylated glioblastoma (GBM) received 60 mg pamiparib orally BID for 2 weeks in combination with up to 60 Gy radiation for 6 weeks

Reporting group title	Arm A: DE-Pamiparib 4 Wks + RT 6 Wks

Reporting group description:

Participants with newly diagnosed unmethylated GBM received 60 mg pamiparib orally for 4 weeks in combination with up to 60 Gy radiation for 6 weeks

Reporting group title	Arm A: DE- Pamiparib 6Wks + RT 6 Wks

Reporting group description:

Participants with newly diagnosed unmethylated GBM received 60 mg pamiparib orally for 6 weeks in combination with up to 60 Gy radiation for 6 weeks

Reporting group title	Arm A: Dose Expansion (E) - Pamiparib 6 Wks + RT 6 Wks

Reporting group description:

Participants with newly diagnosed unmethylated GBM received 60 mg pamiparib orally for 6 weeks in combination with up to 60 Gy radiation for 6 weeks

Reporting group title	Arm B: DE-Pamiparib 6 Wks + RT 6 Wks + Temozolomide

Reporting group description:

Participants with newly diagnosed unmethylated GBM received 60 mg pamiparib orally for 6 weeks in combination with up to 60 Gy radiation for 6 weeks and 60 mg temozolomide Wks 1 and 5

Reporting group title	Arm C: DE – Pamiparib + Temozolomide 20 mg

Reporting group description:

Participants with both methylated and unmethylated recurrent/refractory GBM received 60 mg pamiparib BID and 20 mg temozolomide once daily orally from Day 1 to Day 21

Reporting group title	Arm C: DE – Pamiparib + Temozolomide 40 mg

Reporting group description:

Participants with both methylated and unmethylated recurrent/refractory GBM received 60 mg pamiparib BID and 40 mg temozolomide once daily orally from Day 1 to Day 21

Reporting group title	Arm C: E- Pamiparib + Temozolomide 60 mg

Reporting group description:

Participants with both methylated and unmethylated recurrent/refractory GBM received 60 mg pamiparib BID and 60 mg temozolomide once daily orally from Day 1 to Day 7

Serious adverse events	Arm 1Arm A: DE - Pamiparib 2 Wks + Radiation Therapy (RT) 6 Wk	Arm A: DE- Pamiparib 4 Wks + RT 6 Wks	Arm A: DE- Pamiparib 6Wks + RT 6 Wks
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 3 (0.00%)	2 / 8 (25.00%)	2 / 9 (22.22%)
number of deaths (all causes)	2	7	8
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Malignant melanoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour flare			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			

subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chills			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gait disturbance			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Impaired healing			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Laryngeal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			

Agitation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Confusional state			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haematoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Aphasia			

subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Apraxia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral cyst			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depressed level of consciousness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysaesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysarthria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemiparesis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemiplegia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydrocephalus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Partial seizures			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychogenic seizure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vasogenic cerebral oedema			

subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Anal incontinence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Nausea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Muscular weakness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neck pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			

subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Arm A: Dose Expansion (E) - Pamiparib 6 Wks + RT 6 Wks	Arm B: DE-Pamiparib 6 Wks + RT 6 Wks + Temozolomide	Arm C: DE – Pamiparib + Temozolomide 20 mg
Total subjects affected by serious adverse events			
subjects affected / exposed	18 / 40 (45.00%)	2 / 9 (22.22%)	4 / 9 (44.44%)
number of deaths (all causes)	27	4	8
number of deaths resulting from adverse events	3	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Malignant melanoma			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour flare			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism			

subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chills			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gait disturbance			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Impaired healing			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			

subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Laryngeal haemorrhage			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	3 / 40 (7.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Agitation			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Confusional state			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			

subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haematoma			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Aphasia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Apraxia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain oedema			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Cerebral cyst			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depressed level of consciousness			

subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysaesthesia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysarthria			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemiparesis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemiplegia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydrocephalus			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorder			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Partial seizures			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychogenic seizure			

subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	2 / 40 (5.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 2	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vasogenic cerebral oedema			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 40 (5.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	2 / 2	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			

Anal incontinence			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Muscular weakness			

subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neck pain			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bronchitis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Arm C: DE – Pamiparib + Temozolomide 40 mg	Arm C: E- Pamiparib + Temozolomide 60 mg	
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 8 (37.50%)	11 / 30 (36.67%)	
number of deaths (all causes)	6	21	
number of deaths resulting from adverse events	0	1	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Malignant melanoma			

subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tumour flare			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	1 / 8 (12.50%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolism			
subjects affected / exposed	0 / 8 (0.00%)	2 / 30 (6.67%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chills			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Fatigue			
subjects affected / exposed	1 / 8 (12.50%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gait disturbance			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired healing			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Laryngeal haemorrhage			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	1 / 8 (12.50%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Confusional state			
subjects affected / exposed	1 / 8 (12.50%)	1 / 30 (3.33%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Mental status changes			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicide attempt			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subarachnoid haematoma			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Aphasia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Apraxia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain oedema			

subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral cyst			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular accident			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depressed level of consciousness			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysaesthesia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysarthria			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemiparesis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemiplegia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrocephalus			

subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorder			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Partial seizures			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychogenic seizure			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vasogenic cerebral oedema			
subjects affected / exposed	1 / 8 (12.50%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			

subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Anal incontinence			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	1 / 8 (12.50%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	1 / 8 (12.50%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			

Rash			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Muscular weakness			
subjects affected / exposed	0 / 8 (0.00%)	2 / 30 (6.67%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neck pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Sepsis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection			

subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 3 %

Non-serious adverse events	Arm 1Arm A: DE - Pamiparib 2 Wks + Radiation Therapy (RT) 6 Wk	Arm A: DE-Pamiparib 4 Wks + RT 6 Wks	Arm A: DE-Pamiparib 6Wks + RT 6 Wks
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 3 (100.00%)	8 / 8 (100.00%)	9 / 9 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Renal hamartoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Hypotension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pallor			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Chills			

subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Early satiety			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Fatigue			
subjects affected / exposed	3 / 3 (100.00%)	2 / 8 (25.00%)	6 / 9 (66.67%)
occurrences (all)	3	2	7
Feeling cold			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Gait disturbance			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Swelling face			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Vessel puncture site pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal			

disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Dysphonia			
subjects affected / exposed	0 / 3 (0.00%)	2 / 8 (25.00%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Dyspnoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dyspnoea exertional			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Hiccups			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Hypoxia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Laryngeal inflammation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	1 / 9 (11.11%)
occurrences (all)	0	1	1
Nasal polyps			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Productive cough			

subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pulmonary embolism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Rhinitis allergic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Sinus congestion			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Upper-airway cough syndrome			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Wheezing			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Alcohol abuse			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Anxiety			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Confusional state			
subjects affected / exposed	0 / 3 (0.00%)	2 / 8 (25.00%)	1 / 9 (11.11%)
occurrences (all)	0	2	1
Decreased interest			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

Insomnia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Irritability			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Persistent depressive disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Suicidal ideation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Blood bilirubin increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Blood bilirubin unconjugated increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Cortisol decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count decreased			

subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Neutrophil count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Weight decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
White blood cell count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Eye contusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Ligament sprain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pseudomeningocele			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Radiation injury			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Radiation skin injury			

subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Skin laceration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Subdural haematoma			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Traumatic haematoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Bradycardia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Sinus tachycardia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Ventricular extrasystoles			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Ageusia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Amnesia			
subjects affected / exposed	1 / 3 (33.33%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Aphasia			

subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	3 / 9 (33.33%)
occurrences (all)	0	1	3
Ataxia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Balance disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	2 / 9 (22.22%)
occurrences (all)	0	0	2
Brain oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Carpal tunnel syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Cerebrospinal fluid leakage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Cognitive disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Disturbance in attention			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Drooling			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dysaesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dysarthria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			

subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dyslexia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Encephalopathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Epilepsy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Facial paralysis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Facial paresis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	1 / 3 (33.33%)	1 / 8 (12.50%)	4 / 9 (44.44%)
occurrences (all)	1	1	4
Hemianopia homonymous			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Hemiparesis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Hypersomnia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypoaesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Memory impairment			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Muscle spasticity			

subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Myoclonus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Paraesthesia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	1 / 9 (11.11%)
occurrences (all)	0	1	1
Partial seizures			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	1 / 9 (11.11%)
occurrences (all)	0	1	1
Peripheral motor neuropathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Seizure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Somnolence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Taste disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Tremor			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	2
Visual field defect			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0

Increased tendency to bruise			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Leukopenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Lymphopenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Ear congestion			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Ear discomfort			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Ear pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypoacusis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Tinnitus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	2
Eye disorders			

Dry eye			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Erythema of eyelid			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Lacrimation increased			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	1 / 9 (11.11%)
occurrences (all)	0	1	1
Photophobia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Visual impairment			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Abdominal distension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	1 / 3 (33.33%)	1 / 8 (12.50%)	1 / 9 (11.11%)
occurrences (all)	1	1	1
Breath odour			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Colitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Constipation			

subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	3 / 9 (33.33%)
occurrences (all)	0	1	3
Diarrhoea			
subjects affected / exposed	0 / 3 (0.00%)	2 / 8 (25.00%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Dry mouth			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	1 / 9 (11.11%)
occurrences (all)	0	1	1
Dysphagia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Eructation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Femoral hernia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Haematemesis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hyperaesthesia teeth			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Inguinal hernia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Melaena			

subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Nausea			
subjects affected / exposed	1 / 3 (33.33%)	3 / 8 (37.50%)	5 / 9 (55.56%)
occurrences (all)	1	3	5
Oral dysaesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Retching			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Tooth discolouration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Umbilical hernia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	1 / 3 (33.33%)	0 / 8 (0.00%)	2 / 9 (22.22%)
occurrences (all)	1	0	2
Vomiting projectile			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Hepatic lesion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Alopecia			

subjects affected / exposed	2 / 3 (66.67%)	2 / 8 (25.00%)	2 / 9 (22.22%)
occurrences (all)	2	2	2
Dermatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Dermatitis acneiform			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dermatitis contact			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	1 / 9 (11.11%)
occurrences (all)	0	1	1
Night sweats			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Pain of skin			
subjects affected / exposed	0 / 3 (0.00%)	2 / 8 (25.00%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Petechiae			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	1 / 3 (33.33%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Purpura			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Skin atrophy			

subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Nephrolithiasis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Polyuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Urinary incontinence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Flank pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Groin pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			

subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	1 / 9 (11.11%)
occurrences (all)	0	1	1
Musculoskeletal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pain in jaw			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Tenosynovitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Eye infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hordeolum			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

Oral candidiasis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Osteomyelitis chronic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Otitis media			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Pneumonia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Postoperative wound infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Tooth infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Wound infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Decreased appetite			

subjects affected / exposed	1 / 3 (33.33%)	1 / 8 (12.50%)	3 / 9 (33.33%)
occurrences (all)	1	1	3
Dehydration			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Hyperglycaemia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Hypernatraemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypoalbuminaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypocalcaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Hyponatraemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypophosphataemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Arm A: Dose Expansion (E) - Pamiparib 6 Wks + RT 6 Wks	Arm B: DE-Pamiparib 6 Wks + RT 6 Wks + Temozolomide	Arm C: DE – Pamiparib + Temozolomide 20 mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	40 / 40 (100.00%)	9 / 9 (100.00%)	9 / 9 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Renal hamartoma			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			

Deep vein thrombosis			
subjects affected / exposed	1 / 40 (2.50%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Hypertension			
subjects affected / exposed	1 / 40 (2.50%)	2 / 9 (22.22%)	0 / 9 (0.00%)
occurrences (all)	1	2	0
Hypotension			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences (all)	0	1	1
Pallor			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Chest pain			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Chills			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Early satiety			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	29 / 40 (72.50%)	6 / 9 (66.67%)	1 / 9 (11.11%)
occurrences (all)	34	7	1
Feeling cold			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Gait disturbance			
subjects affected / exposed	2 / 40 (5.00%)	2 / 9 (22.22%)	1 / 9 (11.11%)
occurrences (all)	2	2	1
Influenza like illness			

subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Malaise			
subjects affected / exposed	3 / 40 (7.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	3	0	0
Non-cardiac chest pain			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Oedema peripheral			
subjects affected / exposed	4 / 40 (10.00%)	2 / 9 (22.22%)	1 / 9 (11.11%)
occurrences (all)	4	2	1
Pyrexia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Swelling face			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site pain			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	4 / 40 (10.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	5	0	1
Dysphonia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	1 / 40 (2.50%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Dyspnoea exertional			

subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hiccups			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Hypoxia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	2
Laryngeal inflammation			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	3 / 40 (7.50%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	3	1	0
Nasal polyps			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Pulmonary embolism			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Rhinitis allergic			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Sinus congestion			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Upper-airway cough syndrome			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Wheezing			

subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Agitation			
subjects affected / exposed	4 / 40 (10.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences (all)	4	1	1
Alcohol abuse			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Anxiety			
subjects affected / exposed	6 / 40 (15.00%)	2 / 9 (22.22%)	0 / 9 (0.00%)
occurrences (all)	6	2	0
Confusional state			
subjects affected / exposed	4 / 40 (10.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	5	0	0
Decreased interest			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Depression			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Insomnia			
subjects affected / exposed	6 / 40 (15.00%)	2 / 9 (22.22%)	0 / 9 (0.00%)
occurrences (all)	6	2	0
Irritability			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Persistent depressive disorder			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Suicidal ideation			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Investigations			
Alanine aminotransferase increased			

subjects affected / exposed	3 / 40 (7.50%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	3	0	1
Aspartate aminotransferase increased			
subjects affected / exposed	3 / 40 (7.50%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	3	0	1
Blood bilirubin increased			
subjects affected / exposed	1 / 40 (2.50%)	1 / 9 (11.11%)	2 / 9 (22.22%)
occurrences (all)	4	1	2
Blood bilirubin unconjugated increased			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Blood creatinine increased			
subjects affected / exposed	4 / 40 (10.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	5	0	0
Cortisol decreased			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count decreased			
subjects affected / exposed	3 / 40 (7.50%)	2 / 9 (22.22%)	3 / 9 (33.33%)
occurrences (all)	3	2	3
Neutrophil count decreased			
subjects affected / exposed	6 / 40 (15.00%)	3 / 9 (33.33%)	2 / 9 (22.22%)
occurrences (all)	9	3	2
Platelet count decreased			
subjects affected / exposed	7 / 40 (17.50%)	1 / 9 (11.11%)	3 / 9 (33.33%)
occurrences (all)	8	2	3
Weight decreased			
subjects affected / exposed	9 / 40 (22.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	10	0	0
White blood cell count decreased			

subjects affected / exposed	6 / 40 (15.00%)	4 / 9 (44.44%)	2 / 9 (22.22%)
occurrences (all)	8	7	2
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	3	0	0
Eye contusion			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	5 / 40 (12.50%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	6	1	0
Ligament sprain			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pseudomeningocele			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Radiation injury			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Radiation skin injury			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Skin laceration			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Subdural haematoma			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Traumatic haematoma			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			

Angina pectoris			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Bradycardia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Sinus tachycardia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Ventricular extrasystoles			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Ageusia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Amnesia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Aphasia			
subjects affected / exposed	6 / 40 (15.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences (all)	7	2	1
Ataxia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Balance disorder			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Brain oedema			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Carpal tunnel syndrome			

subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Cerebrospinal fluid leakage			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Cognitive disorder			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	2 / 9 (22.22%)
occurrences (all)	2	0	2
Disturbance in attention			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Dizziness			
subjects affected / exposed	11 / 40 (27.50%)	2 / 9 (22.22%)	1 / 9 (11.11%)
occurrences (all)	12	2	1
Drooling			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dysaesthesia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Dysarthria			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			
subjects affected / exposed	10 / 40 (25.00%)	2 / 9 (22.22%)	1 / 9 (11.11%)
occurrences (all)	11	2	1
Dyslexia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Encephalopathy			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Epilepsy			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Facial paralysis			

subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Facial paresis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Headache			
subjects affected / exposed	18 / 40 (45.00%)	2 / 9 (22.22%)	1 / 9 (11.11%)
occurrences (all)	24	3	1
Hemianopia homonymous			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hemiparesis			
subjects affected / exposed	8 / 40 (20.00%)	3 / 9 (33.33%)	3 / 9 (33.33%)
occurrences (all)	9	3	3
Hypersomnia			
subjects affected / exposed	1 / 40 (2.50%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Hypoaesthesia			
subjects affected / exposed	2 / 40 (5.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	2	1	0
Memory impairment			
subjects affected / exposed	6 / 40 (15.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences (all)	6	1	1
Muscle spasticity			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Myoclonus			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	1 / 40 (2.50%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences (all)	1	1	1
Partial seizures			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Peripheral motor neuropathy			

subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	2
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Seizure			
subjects affected / exposed	6 / 40 (15.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	9	0	1
Somnolence			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Taste disorder			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Visual field defect			
subjects affected / exposed	3 / 40 (7.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	3	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	13 / 40 (32.50%)	4 / 9 (44.44%)	3 / 9 (33.33%)
occurrences (all)	19	7	3
Increased tendency to bruise			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Leukopenia			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Lymphopenia			
subjects affected / exposed	2 / 40 (5.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	2	1	0
Neutropenia			
subjects affected / exposed	2 / 40 (5.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	3	2	0

Thrombocytopenia			
subjects affected / exposed	4 / 40 (10.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	5	1	0
Ear and labyrinth disorders			
Ear congestion			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Ear discomfort			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Ear pain			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Hypoacusis			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Tinnitus			
subjects affected / exposed	3 / 40 (7.50%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	3	1	0
Vertigo			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Dry eye			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Erythema of eyelid			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Lacrimation increased			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Photophobia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Vision blurred			

subjects affected / exposed	3 / 40 (7.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	3	0	0
Visual impairment			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Abdominal pain			
subjects affected / exposed	5 / 40 (12.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	8	0	0
Breath odour			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Colitis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	14 / 40 (35.00%)	3 / 9 (33.33%)	2 / 9 (22.22%)
occurrences (all)	16	3	2
Diarrhoea			
subjects affected / exposed	12 / 40 (30.00%)	2 / 9 (22.22%)	2 / 9 (22.22%)
occurrences (all)	17	2	2
Dry mouth			
subjects affected / exposed	4 / 40 (10.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	4	0	0
Dyspepsia			
subjects affected / exposed	2 / 40 (5.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	2	1	0
Dysphagia			
subjects affected / exposed	1 / 40 (2.50%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	1	1	0

Eructation			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Femoral hernia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Haematemesis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hyperaesthesia teeth			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Inguinal hernia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Melaena			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	29 / 40 (72.50%)	7 / 9 (77.78%)	4 / 9 (44.44%)
occurrences (all)	42	8	4
Oral dysaesthesia			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Retching			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0

Tooth discolouration			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Umbilical hernia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	13 / 40 (32.50%)	2 / 9 (22.22%)	1 / 9 (11.11%)
occurrences (all)	20	2	1
Vomiting projectile			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Hepatic lesion			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Alopecia			
subjects affected / exposed	14 / 40 (35.00%)	4 / 9 (44.44%)	0 / 9 (0.00%)
occurrences (all)	16	4	0
Dermatitis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Dermatitis acneiform			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Dermatitis contact			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Dry skin			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Erythema			

subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Pain of skin			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Pruritus			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Purpura			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Rash maculo-papular			
subjects affected / exposed	1 / 40 (2.50%)	3 / 9 (33.33%)	2 / 9 (22.22%)
occurrences (all)	1	3	2
Skin atrophy			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Nephrolithiasis			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Pollakiuria			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0

Polyuria			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Urinary incontinence			
subjects affected / exposed	6 / 40 (15.00%)	2 / 9 (22.22%)	1 / 9 (11.11%)
occurrences (all)	6	2	1
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 40 (2.50%)	2 / 9 (22.22%)	0 / 9 (0.00%)
occurrences (all)	1	2	0
Back pain			
subjects affected / exposed	3 / 40 (7.50%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences (all)	3	1	1
Flank pain			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Groin pain			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Muscle spasms			
subjects affected / exposed	1 / 40 (2.50%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	1	2	0
Muscular weakness			
subjects affected / exposed	1 / 40 (2.50%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences (all)	1	1	1
Musculoskeletal pain			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	1 / 40 (2.50%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Neck pain			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Pain in extremity			

subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Pain in jaw			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Tenosynovitis			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Eye infection			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hordeolum			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Oral candidiasis			
subjects affected / exposed	1 / 40 (2.50%)	2 / 9 (22.22%)	0 / 9 (0.00%)
occurrences (all)	1	2	0
Oral herpes			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Osteomyelitis chronic			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Otitis media			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Pneumonia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1

Postoperative wound infection			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Sinusitis			
subjects affected / exposed	1 / 40 (2.50%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Tooth infection			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	3	0	0
Urinary tract infection			
subjects affected / exposed	1 / 40 (2.50%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	2	1	0
Wound infection			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	14 / 40 (35.00%)	4 / 9 (44.44%)	2 / 9 (22.22%)
occurrences (all)	15	4	2
Dehydration			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Hyperglycaemia			
subjects affected / exposed	2 / 40 (5.00%)	1 / 9 (11.11%)	2 / 9 (22.22%)
occurrences (all)	3	1	2
Hypernatraemia			
subjects affected / exposed	1 / 40 (2.50%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences (all)	1	1	1
Hypoalbuminaemia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Hypocalcaemia			

subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Hypokalaemia			
subjects affected / exposed	2 / 40 (5.00%)	2 / 9 (22.22%)	0 / 9 (0.00%)
occurrences (all)	2	2	0
Hyponatraemia			
subjects affected / exposed	4 / 40 (10.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	7	0	0
Hypophosphataemia			
subjects affected / exposed	3 / 40 (7.50%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	4	0	1

Non-serious adverse events	Arm C: DE – Pamiparib + Temozolomide 40 mg	Arm C: E- Pamiparib + Temozolomide 60 mg	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	7 / 8 (87.50%)	29 / 30 (96.67%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Renal hamartoma			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Hypertension			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Hypotension			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Pallor			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
General disorders and administration site conditions			

Asthenia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	2	
Chest pain			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Chills			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Early satiety			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Fatigue			
subjects affected / exposed	4 / 8 (50.00%)	17 / 30 (56.67%)	
occurrences (all)	4	20	
Feeling cold			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Gait disturbance			
subjects affected / exposed	1 / 8 (12.50%)	2 / 30 (6.67%)	
occurrences (all)	1	2	
Influenza like illness			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Malaise			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	2	
Non-cardiac chest pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Oedema peripheral			
subjects affected / exposed	0 / 8 (0.00%)	3 / 30 (10.00%)	
occurrences (all)	0	4	
Pyrexia			
subjects affected / exposed	0 / 8 (0.00%)	3 / 30 (10.00%)	
occurrences (all)	0	3	

Swelling face			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Vessel puncture site pain			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Cough			
subjects affected / exposed	0 / 8 (0.00%)	2 / 30 (6.67%)	
occurrences (all)	0	3	
Dysphonia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Dyspnoea			
subjects affected / exposed	0 / 8 (0.00%)	4 / 30 (13.33%)	
occurrences (all)	0	5	
Dyspnoea exertional			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Epistaxis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Hiccups			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Hypoxia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Laryngeal inflammation			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Nasal congestion			

subjects affected / exposed	1 / 8 (12.50%)	3 / 30 (10.00%)	
occurrences (all)	1	3	
Nasal polyps			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Productive cough			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Pulmonary embolism			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Rhinitis allergic			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Sinus congestion			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Upper-airway cough syndrome			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Wheezing			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Alcohol abuse			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Anxiety			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Confusional state			
subjects affected / exposed	0 / 8 (0.00%)	3 / 30 (10.00%)	
occurrences (all)	0	3	

Decreased interest			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Depression			
subjects affected / exposed	0 / 8 (0.00%)	3 / 30 (10.00%)	
occurrences (all)	0	3	
Insomnia			
subjects affected / exposed	1 / 8 (12.50%)	4 / 30 (13.33%)	
occurrences (all)	1	4	
Irritability			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Persistent depressive disorder			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Suicidal ideation			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Blood bilirubin increased			
subjects affected / exposed	1 / 8 (12.50%)	1 / 30 (3.33%)	
occurrences (all)	1	1	
Blood bilirubin unconjugated increased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Blood creatinine increased			
subjects affected / exposed	1 / 8 (12.50%)	2 / 30 (6.67%)	
occurrences (all)	1	3	
Cortisol decreased			

subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Lymphocyte count decreased			
subjects affected / exposed	1 / 8 (12.50%)	4 / 30 (13.33%)	
occurrences (all)	1	5	
Neutrophil count decreased			
subjects affected / exposed	2 / 8 (25.00%)	5 / 30 (16.67%)	
occurrences (all)	2	10	
Platelet count decreased			
subjects affected / exposed	1 / 8 (12.50%)	8 / 30 (26.67%)	
occurrences (all)	1	18	
Weight decreased			
subjects affected / exposed	1 / 8 (12.50%)	3 / 30 (10.00%)	
occurrences (all)	1	3	
White blood cell count decreased			
subjects affected / exposed	1 / 8 (12.50%)	6 / 30 (20.00%)	
occurrences (all)	1	10	
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 8 (0.00%)	3 / 30 (10.00%)	
occurrences (all)	0	3	
Eye contusion			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Fall			
subjects affected / exposed	3 / 8 (37.50%)	5 / 30 (16.67%)	
occurrences (all)	3	8	
Ligament sprain			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Pseudomeningocele			

subjects affected / exposed	1 / 8 (12.50%)	0 / 30 (0.00%)	
occurrences (all)	1	0	
Radiation injury			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Radiation skin injury			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Skin laceration			
subjects affected / exposed	0 / 8 (0.00%)	2 / 30 (6.67%)	
occurrences (all)	0	3	
Subdural haematoma			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Traumatic haematoma			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Bradycardia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Sinus tachycardia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Tachycardia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Ventricular extrasystoles			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Nervous system disorders			
Ageusia			

subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Amnesia			
subjects affected / exposed	0 / 8 (0.00%)	2 / 30 (6.67%)	
occurrences (all)	0	2	
Aphasia			
subjects affected / exposed	0 / 8 (0.00%)	3 / 30 (10.00%)	
occurrences (all)	0	3	
Ataxia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Balance disorder			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Brain oedema			
subjects affected / exposed	1 / 8 (12.50%)	0 / 30 (0.00%)	
occurrences (all)	1	0	
Carpal tunnel syndrome			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Cerebrospinal fluid leakage			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Cognitive disorder			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Disturbance in attention			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Dizziness			
subjects affected / exposed	1 / 8 (12.50%)	8 / 30 (26.67%)	
occurrences (all)	1	8	
Drooling			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Dysaesthesia			

subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Dysarthria			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Dysgeusia			
subjects affected / exposed	0 / 8 (0.00%)	2 / 30 (6.67%)	
occurrences (all)	0	3	
Dyslexia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Encephalopathy			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Epilepsy			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	3	
Facial paralysis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Facial paresis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Headache			
subjects affected / exposed	0 / 8 (0.00%)	8 / 30 (26.67%)	
occurrences (all)	0	11	
Hemianopia homonymous			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Hemiparesis			
subjects affected / exposed	1 / 8 (12.50%)	4 / 30 (13.33%)	
occurrences (all)	1	4	
Hypersomnia			
subjects affected / exposed	0 / 8 (0.00%)	2 / 30 (6.67%)	
occurrences (all)	0	2	
Hypoaesthesia			

subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Memory impairment			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Muscle spasticity			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	2	
Myoclonus			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Paraesthesia			
subjects affected / exposed	0 / 8 (0.00%)	2 / 30 (6.67%)	
occurrences (all)	0	2	
Partial seizures			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Peripheral motor neuropathy			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Seizure			
subjects affected / exposed	0 / 8 (0.00%)	4 / 30 (13.33%)	
occurrences (all)	0	4	
Somnolence			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Taste disorder			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Tremor			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Visual field defect			

subjects affected / exposed	0 / 8 (0.00%)	2 / 30 (6.67%)	
occurrences (all)	0	2	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	3 / 8 (37.50%)	6 / 30 (20.00%)	
occurrences (all)	6	15	
Increased tendency to bruise			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Leukopenia			
subjects affected / exposed	0 / 8 (0.00%)	2 / 30 (6.67%)	
occurrences (all)	0	2	
Lymphopenia			
subjects affected / exposed	0 / 8 (0.00%)	4 / 30 (13.33%)	
occurrences (all)	0	4	
Neutropenia			
subjects affected / exposed	1 / 8 (12.50%)	3 / 30 (10.00%)	
occurrences (all)	1	3	
Thrombocytopenia			
subjects affected / exposed	1 / 8 (12.50%)	3 / 30 (10.00%)	
occurrences (all)	2	3	
Ear and labyrinth disorders			
Ear congestion			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Ear discomfort			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Ear pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Hypoacusis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Tinnitus			

subjects affected / exposed	1 / 8 (12.50%)	1 / 30 (3.33%)	
occurrences (all)	1	1	
Vertigo			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Eye disorders			
Dry eye			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Erythema of eyelid			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Lacrimation increased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Photophobia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Vision blurred			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Visual impairment			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Abdominal distension			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Abdominal pain			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Breath odour			

subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Colitis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Constipation			
subjects affected / exposed	2 / 8 (25.00%)	12 / 30 (40.00%)	
occurrences (all)	2	17	
Diarrhoea			
subjects affected / exposed	1 / 8 (12.50%)	4 / 30 (13.33%)	
occurrences (all)	1	5	
Dry mouth			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Dyspepsia			
subjects affected / exposed	0 / 8 (0.00%)	2 / 30 (6.67%)	
occurrences (all)	0	2	
Dysphagia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Eructation			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Femoral hernia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Flatulence			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 8 (12.50%)	1 / 30 (3.33%)	
occurrences (all)	1	1	
Haematemesis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Hyperaesthesia teeth			

subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Inguinal hernia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	2	
Melaena			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Nausea			
subjects affected / exposed	4 / 8 (50.00%)	13 / 30 (43.33%)	
occurrences (all)	5	18	
Oral dysaesthesia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Retching			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Stomatitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Tooth discolouration			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Umbilical hernia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Vomiting			
subjects affected / exposed	4 / 8 (50.00%)	7 / 30 (23.33%)	
occurrences (all)	5	15	
Vomiting projectile			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Hepatobiliary disorders			
Hepatic lesion			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	2	

Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Alopecia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Dermatitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Dermatitis acneiform			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Dermatitis contact			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Dry skin			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Erythema			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Night sweats			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Pain of skin			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Petechiae			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Pruritus			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Purpura			

subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Rash maculo-papular			
subjects affected / exposed	0 / 8 (0.00%)	2 / 30 (6.67%)	
occurrences (all)	0	2	
Skin atrophy			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Haematuria			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Nephrolithiasis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Pollakiuria			
subjects affected / exposed	1 / 8 (12.50%)	1 / 30 (3.33%)	
occurrences (all)	1	1	
Polyuria			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Urinary incontinence			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 8 (0.00%)	2 / 30 (6.67%)	
occurrences (all)	0	2	
Back pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Flank pain			

subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Groin pain			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Muscle spasms			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Muscular weakness			
subjects affected / exposed	1 / 8 (12.50%)	3 / 30 (10.00%)	
occurrences (all)	1	3	
Musculoskeletal pain			
subjects affected / exposed	0 / 8 (0.00%)	2 / 30 (6.67%)	
occurrences (all)	0	3	
Myalgia			
subjects affected / exposed	0 / 8 (0.00%)	3 / 30 (10.00%)	
occurrences (all)	0	3	
Neck pain			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Pain in extremity			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Pain in jaw			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Tenosynovitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Eye infection			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	

Hordeolum			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Influenza			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Oral candidiasis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	2	
Oral herpes			
subjects affected / exposed	0 / 8 (0.00%)	2 / 30 (6.67%)	
occurrences (all)	0	3	
Osteomyelitis chronic			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Otitis media			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Pneumonia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Postoperative wound infection			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Sinusitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Tooth infection			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Upper respiratory tract infection			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Urinary tract infection			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	

Wound infection			
subjects affected / exposed	0 / 8 (0.00%)	2 / 30 (6.67%)	
occurrences (all)	0	2	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 8 (12.50%)	7 / 30 (23.33%)	
occurrences (all)	1	8	
Dehydration			
subjects affected / exposed	1 / 8 (12.50%)	0 / 30 (0.00%)	
occurrences (all)	1	0	
Hyperglycaemia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Hypernatraemia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Hypoalbuminaemia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Hypocalcaemia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 30 (0.00%)	
occurrences (all)	0	0	
Hypokalaemia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 30 (3.33%)	
occurrences (all)	0	1	
Hyponatraemia			
subjects affected / exposed	1 / 8 (12.50%)	1 / 30 (3.33%)	
occurrences (all)	1	1	
Hypophosphataemia			
subjects affected / exposed	1 / 8 (12.50%)	0 / 30 (0.00%)	
occurrences (all)	1	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
23 July 2018	Overall Inclusion/Exclusion Criteria: Integrated comments received from MHRA regarding contraception language for both males and females and to align this protocol with other pamiparib studies and ensure consistency of language used in describing the process for management of safety. MGMT Analysis: Clarified that the provision of archival tumor tissue for central confirmation of MGMT status is mandatory in the expansion phase of the study because central testing of MGMT promoter status will be done. Criteria Specific to Arm C: To update the criterion for enrollment in Arm C of the study with more precise guidance as to what prior treatments are allowed or excluded and to define the timing of the first progression required for study entry. Overall Study Design: To update that after completion of RT, patients in Arm A (both dose escalation and expansion) and Arm B dose escalation have the option to continue receiving pamiparib in combination with TMZ (maintenance treatment); to note that for Arm B expansion, maintenance treatment of pamiparib in combination with TMZ will be mandatory; and lastly, overall, to make editorial and formatting changes throughout to enhance clarity and readability. Safety: Update the DLT criteria to reflect management of cytopenias in a GBM population and to align this protocol with other pamiparib studies and ensure consistency of language used in describing the process for management of safety.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported